<DOC>
	<DOCNO>NCT00222573</DOCNO>
	<brief_summary>COMMIT/CCS2 large randomise trial effect clopidogrel plus Aspirin versus Aspirin alone acute heart disease . Patients present within 24 hour onset suspect acute MI potentially eligible provide thought ST elevation ischaemic ECG abnormality clear indication , contraindication , trial treatment . All patient give 162 mg ASA daily , addition , 75 mg clopidogrel daily match placebo 4 week prior discharge death . ( Patients also randomise separately 2 X 2 factorial design metoprolol versus placebo . ) The two main study endpoint death composite outcome death , non-fatal reinfarction stroke schedule treatment period hospital .</brief_summary>
	<brief_title>Efficacy Safety Adding Clopidogrel Aspirin Use Metoprolol Myocardial Infarction</brief_title>
	<detailed_description>Clopidogrel Despite considerable improvement emergency treatment acute myocardial infarction ( MI ) , include use aspirin , early mortality morbidity remain high . The antiplatelet agent clopidogrel add benefit aspirin acute coronary syndrome without ST-segment elevation , effect mortality morbidity patient ST-elevation MI unclear . 45,852 patient admitted 1250 hospital within 24 hour onset suspect acute MI randomly allocate receive clopidogrel 75 mg daily match placebo ( addition aspirin 162 mg daily ) . 93 % ST-segment elevation bundle branch block , 7 % ST-segment depression . Treatment continue discharge maximum 4 week hospital ( mean 15 day survivor ) , 93 % complete . The two pre-specified co-primary outcome : ( ) composite death , reinfarction stroke ; ( ii ) death cause schedule treatment period . Comparisons clopidogrel-allocated placebo-allocated patient ( ie , “ intention-to-treat ” ) , use log-rank method . Allocation clopidogrel produce highly significant 9 % ( 95 % CI 3-14 ) proportional reduction primary composite outcome death , reinfarction stroke ( 2121 [ 9.2 % ] clopidogrel v 2310 [ 10.1 % ] placebo ; p=0.002 ) , correspond 9 ( SE 3 ) few event per 1000 patient treat 2 week . There also significant 7 % ( 95 % CI 1-13 ) proportional reduction co-primary outcome death ( 1726 [ 7.5 % ] v 1845 [ 8.1 % ] ; p=0.03 ) . These effect death , reinfarction stroke appear consistent across wide range patient independent treatment use . Considering transfused , fatal cerebral bleeds together , significant excess risk observe clopidogrel , either overall ( 134 [ 0.58 % ] v 125 [ 0.55 % ] ; p=0.59 ) , among patient age 70 year old ( 50 [ 0.84 % ] v 43 [ 0.72 % ] ; p=0.48 ) among give fibrinolytic therapy ( 74 [ 0.65 % ] v 72 [ 0.63 % ] ; p=0.88 ) . In wide range patient acute MI , add clopidogrel 75 mg daily aspirin standard treatment ( fibrinolytic therapy ) reduce mortality major vascular event hospital , without material increase major bleed . Metoprolol Despite previous randomise trial early beta-blocker therapy emergency treatment suspect acute myocardial infarction ( MI ) , substantial uncertainty persist value add currently standard intervention ( eg , aspirin fibrinolytic therapy ) , balance potential benefit hazard unclear even high-risk patient . 45852 patient admitted 1250 hospital within 24 hour onset suspect acute MI randomly allocate receive metoprolol ( 15 mg intravenous follow 200 mg oral daily ) match placebo . 93 % ST-segment elevation bundle branch block , 7 % ST-segment depression . Treatment continue discharge maximum 4 week hospital ( mean 15 day survivor ) , 89 % complete . The two pre-specified co-primary outcome : ( ) composite death , reinfarction cardiac arrest ; ( ii ) death cause schedule treatment period . Comparisons metoprolol-allocated placebo-allocated patient ( ie , “ intention-to-treat ” ) , use log-rank method . Neither co-primary outcome significantly reduce allocation metoprolol . For primary composite outcome death , reinfarction , cardiac arrest , 2166 ( 9.4 % ) patient least one event among 22 929 allocate metoprolol compare 2261 ( 9.9 % ) among 22 923 allocate match placebo ( odds ratio [ OR ] 0.96 [ 95 % CI 0.90-1.01 ] ; p=0.1 ) . For co-primary outcome death alone , 1774 ( 7.7 % ) metoprolol group versus 1797 ( 7.8 % ) placebo group ( OR 0.99 [ 0.92-1.05 ] ; p=0.69 ) . Allocation metoprolol associate 5 few people reinfarction ( 464 [ 2.0 % ] metoprolol v 568 [ 2.5 % ] placebo ; OR 0.82 [ 0.72-0.92 ] ; p=0.001 ) 5 few ventricular fibrillation ( 581 [ 2.5 % ] v 698 [ 3.0 % ] ; OR 0.83 [ 0.75-0.93 ] ; p=0.001 ) per 1000 treat . Overall , reduction counter-balanced 11 per 1000 allocate metoprolol develop cardiogenic shock ( 1141 [ 5.0 % ] v 885 [ 3.9 % ] ; OR 1.30 [ 1.19-1.41 ] ; p &lt; 0.00001 ) . The excess cardiogenic shock chiefly day 0-1 hospitalisation , whereas reduction reinfarction ventricular fibrillation emerge gradually . Consequently , overall effect death , reinfarction , arrest shock significantly adverse day 0-1 significantly beneficial thereafter . There substantial net hazard among haemodynamically unstable patient moderate net benefit among relatively stable , particularly day 0-1 . The use early beta-blocker therapy acute MI reduce risk reinfarction ventricular fibrillation , increase risk cardiogenic shock , especially first day hospitalisation . Consequently , may generally prudent consider start beta-blocker therapy hospital haemodynamic condition follow MI stabilize ( , base previous evidence , continue therapy long-term follow discharge ) .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Patients present ST elevation , leave bundle branch block ST depression within 24 hour onset symptom suspect acute MI clear indication , contraindication , study treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>clopidogrel</keyword>
	<keyword>metoprolol</keyword>
	<keyword>myocardial infarction</keyword>
	<keyword>randomise trial</keyword>
</DOC>